阿替利珠单抗在经治尿路癌特殊人群中的安全性与疗效:SAUL研究亚组分析
SAUL研究纳入1004例经治转移性尿路癌患者,每3周接受阿替利珠单抗1200mg治疗,主要终点为安全性。高龄、肾功能不全或上尿路尿路上皮癌亚组的安全性与疗效与无这些特征的患者相似;ECOG PS 2患者中位总生存仅2.3个月,而ECOG PS 0/1为10.0个月。
要点
- 高龄(≥80岁)和/或肌酐清除率<30 ml/min不排除阿替利珠单抗治疗。
- ECOG PS 2患者预后差,中位OS仅2.3个月,需仔细评估风险获益。
- PD-L1≥5%肿瘤浸润免疫细胞者结局倾向更好,但单臂研究无法定论。
核心结论
- SAUL研究中未被充分研究的人群(高龄、肾功能不全、上尿路尿路上皮癌)结局与II/III期试验更精选人群相似,但ECOG PS 2患者除外。
研究设计与样本
- SAUL研究为单臂研究,纳入1004例经治转移性尿路癌患者,接受阿替利珠单抗1200 mg每3周一次直至疾病进展、不可接受毒性、临床获益丧失或医患决定。
主要发现
- 高龄、肾功能不全或上尿路尿路上皮癌亚组的安全性和疗效与无这些特征的患者相似。
- ECOG PS 2患者具有典型侵袭性疾病临床特征,中位总生存为2.3个月,而ECOG PS 0/1患者为10.0个月。
- PD-L1表达≥5%肿瘤浸润免疫细胞的患者结局倾向于优于<5%者,但单臂研究无法得出相对疗效结论。
关键数值与推荐
- 年龄≥80岁和/或肌酐清除率<30 ml/min不排除阿替利珠单抗给药。
- ECOG PS 2患者需仔细评估治疗风险与获益。
临床怎么用
- 高龄或肾功能不全的经治尿路癌患者可考虑阿替利珠单抗治疗,但ECOG PS 2患者需谨慎权衡风险获益。
局限性
- 单臂研究设计,无法得出阿替利珠单抗相对疗效的结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Atezolizumab is an established treatment option for pretreated urothelial carcinoma, demonstrating efficacy in phase II/III trials. The SAUL study enrolled a broader patient population to determine safety and efficacy in underrepresented subgroups. MATERIALS AND METHODS: Patients with metastatic urinary tract carcinoma received atezolizumab 1,200 mg every 3 weeks until disease progression, unacceptable toxicity, loss of clinical benefit, or patient/physician decision. The primary endpoint was safety. Efficacy was a secondary endpoint. Analyses by programmed cell death ligand-1 (PD-L1) status, age, Eastern Cooperative Oncology Group performance status (ECOG PS) and renal impairment were prespecified; post hoc analyses explored outcomes by tumor location. RESULTS: A total of 1,004 patients were enrolled. Subgroup analyses in patients with older age, renal impairment, or upper tract urothelial carcinoma showed safety and efficacy similar to those in patients without these characteristics. Patients with ECOG PS 2 had clinical features typically associated with aggressive disease; median overall survival was 2.3 months versus 10.0 months in patients with ECOG PS0/1. Patients with PD-L1 expression on ≥5% of tumor-infiltrating immune cells tended to have better outcomes than those with <5% PD-L1 expression, although conclusions on the relative efficacy of atezolizumab cannot be drawn from this single-arm study. CONCLUSIONS: The understudied populations included in the SAUL study had similar outcomes to those in more selected populations included in phase II/III trials of atezolizumab, except for those with ECOG PS 2. Age ≥80 years and/or creatinine clearance <30 ml/minute does not preclude administration of atezolizumab; however, treatment risk versus benefit must be carefully assessed in patients with ECOG PS 2.
引用
- Merseburger AS, Castellano D, Powles T, et al. Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice. J Urol. 2021. PMID: 33835866. doi:10.1097/JU.0000000000001768
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。